Predictive Oncology Surges to 280th Spot with $32 Million Turnover

On March 25, 2025, Predictive Oncology (POAI) experienced a significant surge in trading volume, with a turnover of $32 million, marking an 802.51% increase from the previous day. This surge positioned the company at the 280th spot in the daily stock market rankings. The stock price of POAI rose by 51.57%, marking its third consecutive day of gains and a cumulative increase of 53.64% over the past three days.

Predictive Oncology has successfully developed predictive models derived from 21 unique compounds sourced from the Natural Products Discovery Core at the University of Michigan. These models represent a significant advancement in drug discovery, utilizing the company's active machine learning platform.

The company's innovative approach has led to the identification of three compounds that demonstrate a stronger tumor response compared to Doxorubicin, a standard treatment, across breast, colon, and ovarian cancers. This breakthrough underscores the potential of Predictive Oncology's AI-driven drug discovery capabilities.

In a strategic move, Predictive Oncology has completed the sale of its Skyline Medical assets to DeRoyal Industries. This transaction allows the company to focus on its core AI-driven drug discovery capabilities and integrate seamlessly with Renovaro Biosciences, enhancing its market position and growth prospects.

Predictive Oncology is also in the process of finalizing a definitive merger agreement with Renovaro Biosciences. This merger will facilitate the integration of AI/ML platform technologies, core laboratory capabilities, and business development efforts across Europe and the United States. Renovaro's recent acquisition of BioSymetrics further expands Predictive Oncology's biomarker capabilities, positioning the company for significant growth.

In February 2025, Predictive Oncology closed a registered direct offering, raising funds through the sale of 363,336 shares of common stock. This financial move supports the company's ongoing initiatives in AI-driven drug discovery and biologics, reinforcing its leadership in the field.

Predictive Oncology has also announced positive results from its AI-driven drug repurposing efforts, identifying several abandoned or discontinued drugs for further testing and development in ovarian and other cancer types. This creates significant business development opportunities with large pharmaceutical companies, offering meaningful long-term commercial potential.

The company has partnered with Switzerland-based Tecan Group Ltd. to expand high-throughput drug screening, incorporating human tumor spheroids using automated imaging and 3D analysis. This collaboration leverages Predictive Oncology's vast biobank of cryopreserved live cell tumor specimens, enhancing the production and testing of primary patient tumor spheroids.

Predictive Oncology is planning the European launch of its ChemoFx® Treatment Selection Marker and Tumor Profiling Assay. This initiative targets European clinical trials and provides standard testing to clinicians for individual patients, addressing the estimated 250,000 gynecologic cancers diagnosed annually across Europe.

In January 2025, Predictive Oncology announced an agreement to be acquired by Renovaro. This combination creates immediate scientific synergies by harnessing complementary AI/ML platforms to improve patient outcomes across multiple cancer indications. The deal aligns shareholders' interests, augments business development opportunities, and strengthens the company's positioning in the capital markets.